ArticleFrontiers in nutrition2026
Insulin resistance-related surrogate indices and recurrence of mild hypertriglyceridemic acute pancreatitis: a retrospective cohort study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Surrogate indices related to insulin resistance (IR) may reflect the metabolic abnormalities associated with hypertriglyceridemic acute pancreatitis (HAP). However, their association with disease recurrence remains unclear. Methods: A total of 412 eligible patients with HAP were included. Insulin resistance (IR) was assessed using the triglyceride-glucose index (TyG index), triglyceride-glucose-body mass index (TyG-BMI), metabolic score for insulin resistance (METS-IR), and triglyceride/high-density lipoprotein cholesterol ratio (TG/HDL-C). Associations with HAP recurrence were examined using multivariable logistic regression and restricted cubic spline (RCS) analyses. Predictive and reclassification performances were evaluated using receiver operating characteristic (ROC) curves, net reclassification improvement (NRI), integrated discrimination improvement (IDI), and false discovery rate (FDR) correction. Results: The cumulative recurrence rate of HAP was 41.26%. Following comprehensive covariate adjustment, individuals in the highest quartiles of TyG-BMI (OR = 2.70, 95% CI: 1.42-5.20), METS-IR (OR = 2.62, 95% CI: 1.37-5.06), and TG/HDL-C (OR = 2.21, 95% CI: 1.17-4.22) exhibited a significantly elevated risk of recurrence. These principal associations remained robust after FDR correction. Additionally, RCS modeling confirmed significant dose-response trajectories for the TyG index, TyG-BMI, and METS-IR. Among the evaluated indices, TyG-BMI yielded the numerically highest AUC (0.613). Moreover, discordant outcomes in NRI and IDI analyses relative to alternative indices suggested that no single marker holds absolute predictive superiority. Conclusion: Baseline insulin resistance-related surrogate indices are independently associated with the recurrence of mild HAP. These routine and accessible parameters may serve as practical prognostic indicators for long-term recurrence risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.